AMPLITUDE is the “first trial to show efficacy for the combination of inhibition of PARP and the androgen receptor pathway in metastatic, castration-sensitive prostate cancer with alteration of genes ...

Phase 3 trial results suggest that adjuvant treatment with mitomycin and bacillus Calmette-Guérin (BCG) is as safe and effective as BCG alone for patients with high-risk non-muscle invasive bladder ...

Investigators created a prognostic digital pathology-based AI score to identify a subset of patients with clinically high-risk prostate cancer more likely to benefit from the addition of abiraterone ...

PARP inhibitors demonstrate synergy with radiation, so investigators tested the efficacy and safety of olaparib plus radium-223 in patients with mCRPC and bone metastases in a phase 2 trial.

Investigators presented an interim analysis of the phase 3 ENLIGHTED trial of photodynamic therapy in patients with low-grade upper-tract urothelial cancer.

Rapid reduction of glucocorticoid (GC) doses to 7.5 mg/day or less within 6 months may not worsen renal outcomes or increase relapse in patients with proliferative lupus nephritis (LN), recent study ...

The first trial of adjuvant platinum-based chemotherapy plus paclitaxel in patients with high-risk penile cancer provided some insights.

Medical AI tools for clinicians and patients have advantages and disadvantages, including implicit bias in triage and virtual urgent care.

Data from clinical trials have indicated that PSA is prognostic for outcomes, but little is known about real-world trends.

Health care data breaches that compromised protected health information more than doubled from 2010 to 2024 in the US, data suggest.

Chronic kidney disease (CKD) and hypertension are common health problems among childhood cancer survivors with potentially life-threatening sequelae.

Patients with prostate cancer may have a lower risk of recurrence if they take multivitamin supplements after diagnosis, new data suggest.